keyword
MENU ▼
Read by QxMD icon Read
search

Alzheimer's disease cannabis

keyword
https://www.readbyqxmd.com/read/27886010/discriminative-properties-of-hippocampal-hypoperfusion-in-marijuana-users-compared-to-healthy-controls-implications%C3%A2-for-marijuana-administration%C3%A2-in%C3%A2-alzheimer-s-dementia
#1
Daniel G Amen, Borhan Darmal, Cyrus A Raji, Weining Bao, Lantie Jorandby, Somayeh Meysami, Cauligi S Raghavendra
BACKGROUND: Few studies have evaluated the impact of marijuana use on regional cerebral blood flow. OBJECTIVE: To determine whether perfusion in specific brain regions on functional neuroimaging, including those affected by Alzheimer's disease pathology, are abnormal in marijuana users compared to controls. METHOD: Persons with a diagnosis of cannabis use disorder by DSM-IV and DSM-V criteria (n = 982) were compared to controls (n = 92) with perfusion neuroimaging with SPECT at rest and at a concentration task...
November 24, 2016: Journal of Alzheimer's Disease: JAD
https://www.readbyqxmd.com/read/27884751/a-systematic-review-of-the-effect-of-cannabidiol-on-cognitive-function-relevance-to-schizophrenia
#2
REVIEW
Ashleigh L Osborne, Nadia Solowij, Katrina Weston-Green
BACKGROUND AND OBJECTIVES: Cognitive impairment is a core symptom domain of schizophrenia, neurological disorders and substance abuse. It is characterised by deficits in learning, memory, attention and executive functioning and can severely impact daily living. Antipsychotic drugs prescribed to treat schizophrenia provide limited cognitive benefits and novel therapeutic targets are required. Cannabidiol (CBD), a component of the cannabis plant, has anti-inflammatory and antipsychotic-like properties; however, its ability to improve cognitive impairment has not been thoroughly explored...
November 21, 2016: Neuroscience and Biobehavioral Reviews
https://www.readbyqxmd.com/read/27804883/pros-and-cons-of-medical-cannabis-use-by-people-with-chronic-brain-disorders
#3
Uma Suryadevara, Dawn M Bruijnzeel, Meena Nuthi, Darin A Jagnarine, Rajiv Tandon, Adriaan W Bruijnzeel
BACKGROUND: Cannabis is the most widely used illicit drug in the world and there is growing concern about the mental health effects of cannabis use. These concerns are at least partly due to the strong increase in recreational and medical cannabis use and the rise in tetrahydrocannabinol (THC) levels. Cannabis is widely used to self-medicate by older people and people with brain disorders such as amyotrophic lateral sclerosis (ALS), multiple sclerosis (MS), Alzheimer's disease (AD), Parkinson's disease (PD), bipolar disorder, and schizophrenia...
October 31, 2016: Current Neuropharmacology
https://www.readbyqxmd.com/read/27789118/adverse-structural-and-functional-effects-of-marijuana-on-the-brain-evidence-reviewed
#4
REVIEW
David E Mandelbaum, Suzanne M de la Monte
The growing use and legalization of cannabis are leading to increased exposures across all age groups, including in adolescence. The touting of its medicinal values stems from anecdotal reports related to treatment of a broad range of illnesses including epilepsy, multiple sclerosis, muscle spasms, arthritis, obesity, cancer, Alzheimer disease, Parkinson disease, post-traumatic stress, inflammatory bowel disease, and anxiety. However, it is essential that anecdotal data and the high level of interest in this treatment not obscure objective assessments of any potential and realized short- and long-term adverse effects of cannabis, particularly with respect to age of onset and chronicity of exposure...
September 13, 2016: Pediatric Neurology
https://www.readbyqxmd.com/read/27665036/dazed-and-confused-medical-cannabis-in-alzheimer-disease
#5
Inga M Antonsdottir, Kelly M Makino, Anton P Porsteinsson
No abstract text is available yet for this article.
November 2016: American Journal of Geriatric Psychiatry
https://www.readbyqxmd.com/read/27567873/delineating-the-efficacy-of-a-cannabis-based-medicine-at-advanced-stages-of-dementia-in-a-murine-model
#6
Ester Aso, Pol Andrés-Benito, Isidro Ferrer
Previous reports have demonstrated that the combination of Δ9-tetrahydrocannabinol (Δ9-THC) and cannabidiol (CBD) botanical extracts, which are the components of an already approved cannabis-based medicine, reduce the Alzheimer-like phenotype of AβPP/PS1 transgenic mice when chronically administered during the early symptomatic stage. Here, we provide evidence that such natural cannabinoids are still effective in reducing memory impairment in AβPP/PS1 mice at advanced stages of the disease but are not effective in modifying the Aβ processing or in reducing the glial reactivity associated with aberrant Aβ deposition as occurs when administered at early stages of the disease...
October 4, 2016: Journal of Alzheimer's Disease: JAD
https://www.readbyqxmd.com/read/27400329/therapeutic-approach-to-pain-in-neurodegenerative-diseases-current-evidence-and-perspectives
#7
Marina de Tommaso, Miriam Kunz, Massimiliano Valeriani
INTRODUCTION: Neurodegenerative diseases are increasing in parallel to the lengthening of survival. The management of Alzheimer's disease (AD) and other dementias, Parkinson's disease (PD) and PD-related disorders, and motor neuron diseases (MND), is mainly targeted to motor and cognitive impairment, with special care for vital functions such as breathing and feeding. AREAS COVERED: The present review focuses on chronic pain in main neurodegenerative diseases, addressing current evidence on pain therapeutic management, pain frequency and clinical features, and possible pathophysiological mechanisms...
July 26, 2016: Expert Review of Neurotherapeutics
https://www.readbyqxmd.com/read/27086601/endocannabinoid-system-a-multi-facet-therapeutic-target
#8
REVIEW
Rimplejeet Kaur, Sneha R Ambwani, Surjit Singh
Cannabis sativa is also popularly known as marijuana. It has been cultivated and used by man for recreational and medicinal purposes since many centuries. Study of cannabinoids was at bay for very long time and its therapeutic value could not be adequately harnessed due to its legal status as proscribed drug in most of the countries. The research of drugs acting on endocannabinoid system has seen many ups and downs in the recent past. Presently, it is known that endocannabinoids has role in pathology of many disorders and they also serve "protective role" in many medical conditions...
2016: Current Clinical Pharmacology
https://www.readbyqxmd.com/read/26890764/cannabinoid-receptor-2-participates-in-amyloid-%C3%AE-processing-in-a-mouse-model-of-alzheimer-s-disease-but-plays-a-minor-role-in-the-therapeutic-properties-of-a-cannabis-based-medicine
#9
Ester Aso, Pol Andrés-Benito, Margarita Carmona, Rafael Maldonado, Isidre Ferrer
The endogenous cannabinoid system represents a promising therapeutic target to modify neurodegenerative pathways linked to Alzheimer's disease (AD). The aim of the present study was to evaluate the specific contribution of CB2 receptor to the progression of AD-like pathology and its role in the positive effect of a cannabis-based medicine (1:1 combination of Δ9-tetrahidrocannabinol and cannabidiol) previously demonstrated to be beneficial in the AβPP/PS1 transgenic model of the disease. A new mouse strain was generated by crossing AβPP/PS1 transgenic mice with CB2 knockout mice...
2016: Journal of Alzheimer's Disease: JAD
https://www.readbyqxmd.com/read/26757043/safety-and-efficacy-of-medical-cannabis-oil-for-behavioral-and-psychological-symptoms-of-dementia-an-open-label-add-on-pilot-study
#10
Assaf Shelef, Yoram Barak, Uri Berger, Diana Paleacu, Shelly Tadger, Igor Plopsky, Yehuda Baruch
BACKGROUND: Tetrahydrocannabinol (THC) is a potential treatment for Alzheimer's disease (AD). OBJECTIVE: To measure efficacy and safety of medical cannabis oil (MCO) containing THC as an add-on to pharmacotherapy, in relieving behavioral and psychological symptoms of dementia (BPSD). METHODS: Eleven AD patients were recruited to an open label, 4 weeks, prospective trial. RESULTS: Ten patients completed the trial. Significant reduction in CGI severity score (6...
2016: Journal of Alzheimer's Disease: JAD
https://www.readbyqxmd.com/read/25957927/clinical-trials-of-n-acetylcysteine-in-psychiatry-and-neurology-a-systematic-review
#11
REVIEW
Deepmala, John Slattery, Nihit Kumar, Leanna Delhey, Michael Berk, Olivia Dean, Charles Spielholz, Richard Frye
N-acetylcysteine (NAC) is recognized for its role in acetaminophen overdose and as a mucolytic. Over the past decade, there has been growing evidence for the use of NAC in treating psychiatric and neurological disorders, considering its role in attenuating pathophysiological processes associated with these disorders, including oxidative stress, apoptosis, mitochondrial dysfunction, neuroinflammation and glutamate and dopamine dysregulation. In this systematic review we find favorable evidence for the use of NAC in several psychiatric and neurological disorders, particularly autism, Alzheimer's disease, cocaine and cannabis addiction, bipolar disorder, depression, trichotillomania, nail biting, skin picking, obsessive-compulsive disorder, schizophrenia, drug-induced neuropathy and progressive myoclonic epilepsy...
August 2015: Neuroscience and Biobehavioral Reviews
https://www.readbyqxmd.com/read/25896576/narrative-review-of-the-safety-and-efficacy-of-marijuana-for-the-treatment-of-commonly-state-approved-medical-and-psychiatric-disorders
#12
REVIEW
Katherine A Belendiuk, Lisa L Baldini, Marcel O Bonn-Miller
The present investigation aimed to provide an objective narrative review of the existing literature pertaining to the benefits and harms of marijuana use for the treatment of the most common medical and psychological conditions for which it has been allowed at the state level. Common medical conditions for which marijuana is allowed (i.e., those conditions shared by at least 80 percent of medical marijuana states) were identified as: Alzheimer's disease, amyotrophic lateral sclerosis, cachexia/wasting syndrome, cancer, Crohn's disease, epilepsy and seizures, glaucoma, hepatitis C virus, human immunodeficiency virus/acquired immunodeficiency syndrome, multiple sclerosis and muscle spasticity, severe and chronic pain, and severe nausea...
April 21, 2015: Addiction Science & Clinical Practice
https://www.readbyqxmd.com/read/25788394/cannabinoids-in-late-onset-alzheimer-s-disease
#13
REVIEW
Aia Ahmed, M A van der Marck, Gah van den Elsen, Mgm Olde Rikkert
Given the lack of effective treatments for late-onset Alzheimer's disease (LOAD) and the substantial burden on patients, families, health care systems, and economies, finding an effective therapy is one of the highest medical priorities. The past few years have seen a growing interest in the medicinal uses of cannabinoids, the bioactive components of the cannabis plant, including the treatment of LOAD and other physical conditions that are common in older people. Several in vitro and in vivo studies have demonstrated that cannabinoids can reduce oxidative stress, neuroinflammation, and the formation of amyloid plaques and neurofibrillary tangles, the key hallmarks of LOAD...
June 2015: Clinical Pharmacology and Therapeutics
https://www.readbyqxmd.com/read/25601726/cannabinoid-signaling-and-neuroinflammatory-diseases-a-melting-pot-for-the-regulation-of-brain-immune-responses
#14
REVIEW
Valerio Chiurchiù, Alessandro Leuti, Mauro Maccarrone
The concept of the central nervous system (CNS) as an immune-privileged site, essentially due to the presence of the blood brain barrier, appears to be overly simplistic. Indeed, within healthy CNS immune activities are permitted and are required for neuronal function and host defense, not only due to the presence of the resident innate immune cells of the brain, but also by virtue of a complex cross-talk of the CNS with peripheral immune cells. Nonetheless, long-standing and persisting neuroinflammatory responses are most often detrimental and characterize several neuroinflammatory diseases, including multiple sclerosis, Alzheimer's disease and amyotrophic lateral sclerosis...
June 2015: Journal of Neuroimmune Pharmacology: the Official Journal of the Society on NeuroImmune Pharmacology
https://www.readbyqxmd.com/read/25125475/cannabis-based-medicine-reduces-multiple-pathological-processes-in-a%C3%AE-pp-ps1-mice
#15
Ester Aso, Alexandre Sánchez-Pla, Esteban Vegas-Lozano, Rafael Maldonado, Isidro Ferrer
Several recent findings suggest that targeting the endogenous cannabinoid system can be considered as a potential therapeutic approach to treat Alzheimer's disease (AD). The present study supports this hypothesis demonstrating that delta-9-tetrahydrocannabinol (THC) or cannabidiol (CBD) botanical extracts, as well as the combination of both natural cannabinoids, which are the components of an already approved cannabis-based medicine, preserved memory in AβPP/PS1 transgenic mice when chronically administered during the early symptomatic stage...
2015: Journal of Alzheimer's Disease: JAD
https://www.readbyqxmd.com/read/25054066/identification-of-potential-herbal-inhibitor-of-acetylcholinesterase-associated-alzheimer-s-disorders-using-molecular-docking-and-molecular-dynamics-simulation
#16
Chandrabhan Seniya, Ghulam Jilani Khan, Kuldeep Uchadia
Cholinesterase inhibitors (ChE-Is) are the standard for the therapy of AD associated disorders and are the only class of approved drugs by the Food and Drug Administration (FDA). Additionally, acetylcholinesterase (AChE) is the target for many Alzheimer's dementia drugs which block the function of AChE but have some side effects. Therefore, in this paper, an attempt was made to elucidate cholinesterase inhibition potential of secondary metabolite from Cannabis plant which has negligible or no side effect. Molecular docking of 500 herbal compounds, against AChE, was performed using Autodock 4...
2014: Biochemistry Research International
https://www.readbyqxmd.com/read/24288245/cannabidiol-promotes-amyloid-precursor-protein-ubiquitination-and-reduction-of-beta-amyloid-expression-in-shsy5yapp-cells-through-ppar%C3%AE-involvement
#17
Caterina Scuderi, Luca Steardo, Giuseppe Esposito
The amyloidogenic cascade is regarded as a key factor at the basis of Alzheimer's disease (AD) pathogenesis. The aberrant cleavage of amyloid precursor protein (APP) induces an increased production and a subsequent aggregation of beta amyloid (Aβ) peptide in limbic and association cortices. As a result, altered neuronal homeostasis and oxidative injury provoke tangle formation with consequent neuronal loss. Cannabidiol (CBD), a Cannabis derivative devoid of psychotropic effects, has attracted much attention because it may beneficially interfere with several Aβ-triggered neurodegenerative pathways, even though the mechanism responsible for such actions remains unknown...
July 2014: Phytotherapy Research: PTR
https://www.readbyqxmd.com/read/24267894/%C3%AE-9-thc-caused-synaptic-and-memory-impairments-are-mediated-through-cox-2-signaling
#18
Rongqing Chen, Jian Zhang, Ni Fan, Zhao-Qian Teng, Yan Wu, Hongwei Yang, Ya-Ping Tang, Hao Sun, Yunping Song, Chu Chen
Marijuana has been used for thousands of years as a treatment for medical conditions. However, untoward side effects limit its medical value. Here, we show that synaptic and cognitive impairments following repeated exposure to Δ(9)-tetrahydrocannabinol (Δ(9)-THC) are associated with the induction of cyclooxygenase-2 (COX-2), an inducible enzyme that converts arachidonic acid to prostanoids in the brain. COX-2 induction by Δ(9)-THC is mediated via CB1 receptor-coupled G protein βγ subunits. Pharmacological or genetic inhibition of COX-2 blocks downregulation and internalization of glutamate receptor subunits and alterations of the dendritic spine density of hippocampal neurons induced by repeated Δ(9)-THC exposures...
November 21, 2013: Cell
https://www.readbyqxmd.com/read/23829369/acute-and-non-acute-effects-of-cannabis-on-human-memory-function-a-critical-review-of-neuroimaging-studies
#19
REVIEW
Matthijs G Bossong, Gerry Jager, Sagnik Bhattacharyya, Paul Allen
Smoking cannabis produces a diverse range of effects, including impairments in learning and memory. These effects are exerted through action on the endocannabinoid system, which suggests involvement of this system in human cognition. Learning and memory deficits are core symptoms of psychiatric and neurological disorders such as schizophrenia and Alzheimer's disease, and may also be related to endocannabinoid dysfunction in these disorders. However, before new research can focus on potential treatments that work by manipulating the endocannabinoid system, it needs to be elucidated how this system is involved in symptoms of psychiatric disorders...
2014: Current Pharmaceutical Design
https://www.readbyqxmd.com/read/23471521/cannabinoid-receptor-2-potential-role-in-immunomodulation-and-neuroinflammation
#20
REVIEW
Slava Rom, Yuri Persidsky
An accumulating body of evidence suggests that endocannabinoids and cannabinoid receptors type 1 and 2 (CB(1), CB(2)) play a significant role in physiologic and pathologic processes, including cognitive and immune functions. While the addictive properties of marijuana, an extract from the Cannabis plant, are well recognized, there is growing appreciation of the therapeutic potential of cannabinoids in multiple pathologic conditions involving chronic inflammation (inflammatory bowel disease, arthritis, autoimmune disorders, multiple sclerosis, HIV-1 infection, stroke, Alzheimer's disease to name a few), mainly mediated by CB(2) activation...
June 2013: Journal of Neuroimmune Pharmacology: the Official Journal of the Society on NeuroImmune Pharmacology
keyword
keyword
91736
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"